2025-05-14T14:54:52-05:00 2024-06-30 991856619 GRANT THORNTON ADVISORS LLC 5955 TG LEE BLVD STE 200 ORLANDO FL 32822 990 2023-07-01 592451713 H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC HLEE 8137454673 12902 MAGNOLIA DRIVE TAMPA FL 33612 JOANNA WEISS EVP/CFO 8137451188 2025-05-14 0 MICHELE N MELCHIOR P00488037 4074815100 2023 2025-03-06 01:10:19Z DR PATRICK HWU 12902 MAGNOLIA DRIVE TAMPA FL 33612 542549143 0 X WWW.MOFFITT.ORG X 1984 FL TO PROMOTE AND SUPPORT THROUGH RESEARCH, MANAGEMENT AND OTHER MEANS OF SUPPORT. 26 26 3507 111 10288136 5006604 223705693 265672115 21838039 20372705 58731977 25401260 5775019 3365854 310050728 314811934 750767 5205659 0 0 189766622 211694718 0 0 0 111206123 123413348 301723512 340313725 8327216 -25501791 2420012918 2863960572 1190201187 1455722640 1229811731 1408237932 X TO PROMOTE AND SUPPORT MOFFITT SUBSIDIARIES THROUGH RESEARCH, MANAGEMENT, AND OTHER MEANS OF SUPPORT. 0 0 236199479 5205659 20372705 THE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. IS ARECOGNIZED LEADER IN FOCUSED, INNOVATIVE CANCER RESEARCH, A MAJORREGIONAL ONCOLOGY REFERRAL CENTER, AND A NATIONAL CANCER INSTITUTE DESIGNATED COMPREHENSIVE CANCER CENTER.SEE SCHEDULE O FOR CONTINUATIONBASED ON ITS SINGULAR MISSION - TO CONTRIBUTE TO THE PREVENTION ANDCURE OF CANCER - THE CANCER CENTER'S RESEARCH ACTIVITIES RELATEPRIMARILY TO THE AREAS OF BASIC SCIENCE, CANCER PREVENTION AND CONTROL, TRANSLATIONAL SCIENCE, PRE-CLINICAL AND CLINICAL INVESTIGATIONS, AND PROVIDING MANAGEMENT AND OTHER SUPPORT SERVICES AS THE SOLE CORPORATE MEMBER AND PARENT FOR THE FOLLOWING SUBSIDIARY CORPORATIONS:H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. (THE HOSPITAL) WHICH PROVIDES MEDICAL AND HOSPITAL CARE, MEDICAL EDUCATION AND TRAINING, AND CLINICAL (PATIENT-RELATED) RESEARCH IN MAINTAINING HEALTH, AND PREVENTING, DETECTING, AND TREATING CANCER;H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE LIFETIME CANCERSCREENING CENTER, INC. (MOFFITT MEDICAL GROUP) WHICH EMPLOYS ANDMANAGES PHYSICIANS AND OTHER MEDICAL PROFESSIONALS WHO STAFF THEHOSPITAL, AND PROVIDE CLINICAL RESEARCH SERVICES TO THE CANCER CENTER; H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION, INC. (THE FOUNDATION) WHICH IS THE PRINCIPAL FUND-RAISING ORGANIZATION FOR THE CANCER CENTER AND ITS SUBSIDIARIES.; MOFFITT REAL ESTATE HOLDING CORPORATION WHICH HOLDS THE REAL ESTATE TITLE TO THE 775 ACRE "SPEROS" RESEARCH CAMPUS CURRENTLY BEING CONSTRUCTED IN PASCO COUNTY, FL; AND MOFFITT LIFESCIENCES CAMPUS MANAGEMENT CORPORATION WHICH WILL BE THE GROUND LESSEE OF THE SPEROS PROPERTY.THE CANCER CENTER'S MULTIDISCIPLINARY CLINICAL PROGRAM STRUCTURE AND OPEN LABORATORY ARCHITECTURE PROVIDE AN ENVIRONMENT CONDUCIVE FOR TRAINING FUTURE SCIENTIFIC AND CLINICAL LEADERS IN ONCOLOGY, AND REFLECT THE CANCER CENTER'S COMMITMENT TO COLLABORATION IN ALL ASPECTS OF CANCER RESEARCH. 236199479 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 0 1 0 1 1 1 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 1 1 1 0 0 1 501 0 1 3507 1 1 1 0 0 0 0 0 0 0 0 0 1 0 X 26 26 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 X JOANNA WEISS 8137451188 12902 MAGNOLIA DR TAMPA FL 33612 X TIMOTHY J ADAMS DIRECTOR, CHAIR 1.00 1.00 X X 0 0 0 BETH A HOUGHTON DIRECTOR, VICE CHAIR 1.00 1.00 X X 0 0 0 BENJAMIN H HILL III ESQ DIRECTOR, SECRETARY/TREASURER 1.00 1.00 X X 0 0 0 ALAN LEVINE DIRECTOR TO 2/2024 1.00 0.00 X 0 0 0 ALLISON ADAMS DIRECTOR 1.00 0.00 X 0 0 0 ANGELA BIEVER DIRECTOR 1.00 0.00 X 0 0 0 CARLOS ALFONSO DIRECTOR 1.00 0.00 X 0 0 0 EDISON LIU DIRECTOR 1.00 1.00 X 0 0 0 EDWARD C DROSTE DIRECTOR 1.00 1.00 X 0 0 0 EDWARD DEBARTOLO DIRECTOR 1.00 0.00 X 0 0 0 FRANCISCO SANCHEZ DIRECTOR 1.00 0.00 X 0 0 0 GEOFFREY M DUYK PHD MD DIRECTOR 1.00 0.00 X 0 0 0 JESSICA COSTELLO DIRECTOR 1.00 0.00 X 0 0 0 JOHN RAMIL DIRECTOR 1.00 0.00 X 0 0 0 JOHN TOMLIN DIRECTOR 1.00 0.00 X 0 0 0 JOSEPH CABALLERO DIRECTOR 1.00 2.00 X 0 0 0 KEN JONES DIRECTOR AS OF 2/2024 1.00 0.00 X 0 0 0 LIZ SMITH DIRECTOR 1.00 0.00 X 0 0 0 PAMELA STEWART DIRECTOR 1.00 0.00 X 0 0 0 REGINALD GOINS DIRECTOR 1.00 1.00 X 0 0 0 RHEA LAW DIRECTOR 1.00 0.00 X 0 0 0 ROSE BAKER REILLY DIRECTOR 1.00 1.00 X 0 0 0 THE HON CARL CARPENTER DIRECTOR 1.00 0.00 X 0 0 0 THE HON H LEE MOFFITT ESQ DIRECTOR 1.00 2.00 X 0 0 0 THE HON JOHN A GRANT ESQ DIRECTOR 1.00 0.00 X 0 0 0 THE HON JAMES T HARGRETT ESQ DIRECTOR 1.00 0.00 X 0 0 0 VALERIE GODDARD DIRECTOR 1.00 1.00 X 0 0 0 VALERIE MONTGOMERY RICE DIRECTOR TO 3/2024 1.00 0.00 X 0 0 0 PATRICK HWU PRES/CEO 51.00 5.00 X 1574762 0 153522 YVETTE M LYONS TREMONTI EVP-CFAO & ASST TREASURER TO 5/2024 20.00 36.00 X 1042682 0 397146 G DOUGLAS LETSON EVP-PIC TO 6/2024 15.00 40.00 X 0 1073620 302795 L DAVID DE LA PARTE EVP GEN COUNS & ASST SEC TO 6/2024 20.00 36.00 X 865274 0 392072 JOHN CLEVELAND EVP-CENTER DIRECTOR 55.00 1.00 X 901209 0 238031 JONATHAN ZAGER CHIEF ACADEMIC OFFICER 35.00 20.00 X 0 799904 317941 SARABDEEP SINGH EVP COO 15.00 40.00 X 872462 0 120699 EDMONDO ROBINSON SVP CHIEF DIGITAL INNOV TO 1/2024 55.00 0.00 X 742999 0 131701 WJ WILSON VP GOVT RELATIONS 55.00 0.00 X 443914 0 321312 BRIAN SPRINGER VP RESEARCH ADMINISTRATION 55.00 0.00 X 595944 0 159918 DANA E ROLLISON VP CHIEF DATA OFFICER 55.00 0.00 X 486986 0 239829 JOANNA WEISS EVP-CFAO & ASST TREAS AS OF 5/2024 22.00 33.00 X 528314 0 191655 DIANE HAMMON VP CHIEF STRATEGY OFFICER TO 4/2024 55.00 0.00 X 566989 0 85015 CHARLES FLETCHER VP DEPUTY GENERAL COUNSEL 40.00 16.00 X 420464 0 131647 JARETT RIEGER VP CHIEF INNOVATION OFFICER 55.00 0.00 X 332979 0 216089 JOYCE OH VP INFO TECH & CIO 55.00 0.00 X 465755 0 36857 AMY DURHAM VP-HUMAN RECOURCES OPS 55.00 0.00 X 414534 0 85702 XAVIER AVAT EVP-CHIEF BUS OFFICER AS OF 7/2023 55.00 0.00 X 477549 0 21012 HENRY REYES VP-PARTNERSHIP DEVELOP TO 4/2024 20.00 35.00 X 200263 203176 72652 DONALD FUTRELL VP PLAN, DESIGN & CONS TO 5/2024 55.00 0.00 X 412876 0 60525 JASON LEBSACK VP-CLINICAL TRIALS/OPS 55.00 0.00 X 359658 0 103398 EVAN ZASLOW VP PAYER STRATEGIES 15.00 40.00 X 0 389889 63653 CATHY GRANT VP CHIEF DIV, EQTY & INCLUS OFFICER 55.00 0.00 X 302985 0 142159 LYNN ANSLEY VP-REVENUE CYCLE 55.00 0.00 X 330376 0 101709 TERRENCE WRIGHT VP-FAC & SUP SVCS 30.00 25.00 X 346707 0 71550 MERRITT MARTIN VP-PUB AFF, STRAT COMM, COS, EXT AFF AS OF 10/202 55.00 0.00 X 260780 0 144198 JOHN JACK MCKENNA SR VP-CHIEF HR OFFICER AS OF 7/2023 55.00 0.00 X 379588 0 15251 BRADLEY POLLITT VP-PLAN, DESIGN & CONT AS OF 10/2023 55.00 0.00 X 65451 0 3509 ELIZABETH LINDSAY-WOOD VP-CIO & TECH OFFICER AS OF 6/2024 55.00 0.00 X 0 0 0 KAREN LU EVP-PIC AS OF 6/2024 15.00 40.00 X 0 0 0 JENNIFER BONILLA VP-PORTFOLIO STRATEGY AS OF 3/2024 55.00 0.00 X 0 0 0 LEANDRO CHRISTMANN VP-VENTURES & INVEST AS OF 3/2024 55.00 0.00 X 0 0 0 ANNA GIULIANO DIRECTOR CENTER OF EXCELLENCE 50.00 0.00 X 505697 0 297476 JAMES J MULAY ACD TRANSLATIONAL RSCH 50.00 1.00 X 638119 0 103430 RANDA M PERKINS CHIEF MEDICAL INFO OFFICER 50.00 0.00 X 475742 0 99203 ELSA FLORES ACD BASIC SCIENCE 50.00 0.00 X 434640 0 138153 SHELLEY TWOROGER ACD POPULATION SCIENCE 50.00 0.00 X 424635 0 116510 LYNN MOSCINSKI FRM CHIEF ACADEM OFFICER TO 6/2019 0.00 50.00 X 0 499748 228741 B LEE GREEN FRM VP DIV, PR & STRAT AS OF 8/2022 50.00 0.00 X 346031 0 266964 KENNETH KOMORNY FRM VP CHIEF PHARM OFF AS OF 6/2023 0.00 55.00 X 0 308788 89669 SANTOSH MOHAN FRM VP-DIGITAL AS OF 6/2023 50.00 0.00 X 347677 0 45282 16564041 3275125 5706975 601 1 1 0 BARR & BARR INC 460 W 34TH ST FL 10 NEW YORK NY 10001 PROFESSIONAL SERVICES 42593891 BIRDSALL VOSS & ASSOCIATES INC 250 W COVENTRY CT STE 300 MILWAUKEE WI 532173966 MARKETING SERVICES 9703887 TSOIKOBUS & ASSOCIATES INC 60 STATE ST STE 1800 BOSTON MA 02109 ENGINEERING SERVICES 7418245 GARDNER BREWER HUDSON PA 400 N ASHLEY DR STE 1100 TAMPA FL 33602 LEGAL SERVICES 3980424 MODUS DIRECT LLC 1343 MAIN ST STE 600 SARASOTA FL 342365630 MARKETING SERVICES 3368500 113 37340776 172538821 55792518 19773519 265672115 CELL THERAPY PRODUCTS 541900 7603951 3351230 4252721 MANAGEMENT SERVICES 541700 6403658 0 6403658 CORE LAB REVENUE 541610 5666674 5666674 0 CLINICAL TRIAL COLLABORATION 541700 250000 250000 RESEARCH COLLABORATION 541700 194414 194414 0 254008 254008 20372705 21873687 -488243 22361930 914381 914381 559495 0 559495 559495 120000 439495 213933385 16417016 227709070 28139 -13775685 16388877 2613192 2613192 PARKING 900099 939113 939113 LICENSE FEES 900099 823907 823907 REBATES 900099 324991 324991 718348 718348 2806359 314811934 10630707 10288136 28220976 X 5148330 5148330 57329 57329 15231013 12762827 2468186 745092 624350 120742 160668199 109837326 50830873 7297358 5026862 2270496 17347191 13513817 3833374 10405865 7089769 3316096 2725835 2725835 67762 67762 110185 110185 1570793 1570793 30213906 18615649 11598257 4144596 71844 4072752 25223025 18063820 7159205 13227260 1026349 12200911 5377052 3202 5373850 4458616 1465873 2992743 1838717 1838717 11252227 11252227 290740 290740 INCOME TAX EXPENSE 1445264 0 1445264 ALLOCATION OF I/C EXPEN 0 24942411 -24942411 CORE RESEARCH COSTS 7536348 7456121 80227 MEDICAL SUPPLIES 5077927 5069564 8363 8853095 5424036 3429059 340313725 236199479 104114246 0 155843806 376455271 684880809 708497254 24992183 30821585 27930120 31906151 1715984541 614231485 994769143 1101753056 372004110 419470040 30740000 15878300 128852747 179178915 2420012918 2863960572 177580502 200646922 3956594 606425 984150028 1174013346 24514063 80455947 1190201187 1455722640 X 1129464847 1298767266 100346884 109470666 1229811731 1408237932 2420012918 2863960572 X -25501791 36432302 167495690 X 0 1 X 1 1 1 X 180471501 175685146 197374169 223705693 265672115 1042908624 180471501 175685146 197374169 223705693 265672115 1042908624 1042908624 6162666 5483559 6254190 14956856 23227563 56084834 10846860 14952638 8804380 8468496 5006604 48078978 2314119 2743929 2538246 5198052 2806359 15600705 1162673141 38438673 0.89700 0.89840 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: LICENSE FEES - 2019 AMOUNT: $ 291,471. 2020 AMOUNT: $ 1,307,836. 2021 AMOUNT: $ 915,644. 2022 AMOUNT: $ 1,101,075. 2023 AMOUNT: $ 823,907. PARKING - 2019 AMOUNT: $ 889,946. 2020 AMOUNT: $ 752,340. 2021 AMOUNT: $ 1,004,791. 2022 AMOUNT: $ 992,164. 2023 AMOUNT: $ 939,113. LEASES - 2019 AMOUNT: $ 32,016. 2020 AMOUNT: $ 76,012. 2021 AMOUNT: $ 25,894. 2022 AMOUNT: $ 15,912. 2023 AMOUNT: $ 28,269. STAFF RETAIL SERVICES - 2019 AMOUNT: $ 33,888. 2020 AMOUNT: $ 23,681. 2021 AMOUNT: $ 56,458. 2022 AMOUNT: $ 29,857. 2023 AMOUNT: $ 26,506. GIFT SHOP - 2022 AMOUNT: $ 51,138. 2023 AMOUNT: $ 119,561. SUPPORT ACCOUNTS - 2019 AMOUNT: $ 758,853. REBATES/REFUNDS - 2019 AMOUNT: $ 171,326. 2020 AMOUNT: $ 161,862. 2021 AMOUNT: $ 342,083. 2022 AMOUNT: $ 414,397. 2023 AMOUNT: $ 350,566. MISC - 2019 AMOUNT: $ 11,786. 2020 AMOUNT: $ 21,788. 2021 AMOUNT: $ 19,262. 2022 AMOUNT: $ 8,544. 2023 AMOUNT: $ 11,692. REIMBURSEMENT OF EXPENSES - 2019 AMOUNT: $ 55,568. 2020 AMOUNT: $ 116,640. 2021 AMOUNT: $ 111,395. 2022 AMOUNT: $ 148,730. 2023 AMOUNT: $ 240,957. PATENT EXPENSE REIMBURSEMENT - 2019 AMOUNT: $ 69,265. 2020 AMOUNT: $ 67,484. 2021 AMOUNT: $ 62,719. 2022 AMOUNT: $ 89,327. 2023 AMOUNT: $ 116,695. UNCLAIMED PROPERTY - 2020 AMOUNT: $ 216,286. 2023 AMOUNT: $ 149,093. BOND CLOSING PROCEEDS - 2022 AMOUNT: $ 2,346,908. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 1 12221 1 4601 1 5007 0 1 61837 1 10462 1 114677 208805 0 PART II-B, LINE 1: THE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. AND ITS FIVE NON-PROFIT SUBSIDIARY CORPORATIONS ("CORPORATION") WERE CREATED TO GOVERN AND OPERATE THE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE ("INSTITUTE") PURSUANT TO SECTION 1004.43, FLORIDA STATUTES. AMONG OTHER THINGS, SECTION 1004.43, FLORIDA STATUTES PROVIDES: (1) THAT THE CORPORATION SHALL ENTER INTO AN AGREEMENT WITH THE STATE BOARD OF EDUCATION FOR THE UTILIZATION OF FACILITIES ON THE CAMPUS OF THE UNIVERSITY OF SOUTH FLORIDA; (2) THAT THE CORPORATION SUBMIT ANNUAL POST AUDITS OF ITS FINANCIAL ACCOUNTS TO THE AUDITOR GENERAL OF THE STATE OF FLORIDA AND THE BOARD OF GOVERNORS FOR THEIR REVIEW; AND (3) THAT THE CORPORATION'S CEO REPORT TO THE BOARD OF GOVERNORS OR ITS DESIGNEE AND PROVIDE COPIES OF THE INSTITUTE'S ANNUAL REPORT TO THE GOVERNOR OF THE STATE OF FLORIDA, THE CABINET, THE PRESIDENT OF THE SENATE, THE SPEAKER OF THE HOUSE AND THE CHAIR OF THE BOARD OF GOVERNORS. ALTHOUGH THE CORPORATION IS A PRIVATE ENTITY, IT IS NONETHELESS SUBJECT TO THE STATE OF FLORIDA'S PUBLIC RECORDS AND THE PUBLIC MEETINGS LAWS. THE CORPORATION ALSO RELIES ON ANNUAL APPROPRIATIONS BY THE LEGISLATURE OF THE STATE OF FLORIDA AND GRANTS FROM VARIOUS LOCAL, STATE AND FEDERAL AGENCIES FOR OPERATION AND MAINTENANCE OF ITS FACILITIES AND FOR SPECIFIC RESEARCH AND CLINICAL PROGRAMS. FOR THESE REASONS, THE CORPORATION FROM TIME TO TIME ENGAGES LOBBYISTS AND OTHER CONSULTANTS; (1) TO ASSIST IT IN COMPLYING WITH ITS REPORTING REQUIREMENTS TO THE STATE OF FLORIDA UNDER SECTION 1004.43, FLORIDA STATUTES; (2) TO MONITOR LEGISLATIVE AND EXECUTIVE BRANCH ACTION AT LOCAL, STATE AND FEDERAL LEVELS OF GOVERNMENT WHICH IMPACT ITS OPERATION AND THE FULFILLMENT OF ITS MISSION; AND (3) TO INFLUENCE LEGISLATION IN FURTHERANCE OF ITS MISSION IN THE AREAS OF CANCER RESEARCH AND TREATMENT, THE TEACHING AND TRAINING OF HEALTH CARE PROFESSIONALS AND COMMUNITY EDUCATION AND OUTREACH ACTIVITIES. THE CORPORATION DOES NOT ENGAGE IN ANY ACTIVITIES TO SUPPORT OR OPPOSE ANY CANDIDATE FOR PUBLIC OFFICE. PART II-B, LINE 1I, OTHER ACTIVITIES THE OTHER ACTIVITIES AMOUNT LISTED ON LINE 1I IS COMPRISED OF EXPENSES RELATED TO ORCHESTRATING CONTACT BETWEEN GRASSROOTS SUPPORTERS (WHO ARE VOLUNTEERS) AND ELECTED OFFICIALS TO PROMOTE THE INSTITUTION'S LEGISLATIVE OBJECTIVES. 22187330 22187330 1012860916 318521892 694339024 3136748 3133146 3602 480650017 292576447 188073570 197149530 197149530 1101753056 INTEREST IN NET ASSETS OF FOUNDATION 80021423 RECEIVABLES FROM CONTROLLED ORGS 11717846 OTHER RECEIVABLES 4329079 RIGHT OF USE ASSET-OPERATING 28636756 OTHER ASSETS 400000 RIGHT OF USE ASSET-FINANCE LEASE 54073811 179178915 LEASE OBLIGATIONS 17379200 OTHER LIABILITIES 561949 FINANCE LEASE LIABILITY-L/T 42121618 BOND INTEREST PAYABLE-L/T 20393180 80455947 X PART X, LINE 2: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. DID NOT HAVE ANY UNCERTAIN POSITIONS IN ITS AUDITED FINANCIAL STATEMENTS. THE ASC-740 FOOTNOTE READS AS FOLLOWS: SIGNIFICANT JUDGMENT IS REQUIRED TO EVALUATE UNCERTAIN TAX POSITIONS. THE CANCER CENTER EVALUATES ITS UNCERTAIN TAX POSITIONS ON A REGULAR BASIS. ITS EVALUATIONS ARE BASED ON A NUMBER OF FACTORS, INCLUDING CHANGES IN FACTS AND CIRCUMSTANCES, CHANGES IN TAX LAW, AND CORRESPONDENCE WITH TAX AUTHORITIES. THE CANCER CENTER ACCOUNTS FOR UNCERTAIN TAX POSITIONS BY RECOGNIZING A TAX BENEFIT OR LIABILITY AT THE LARGEST AMOUNT THAT, IN ITS JUDGMENT, IS MORE THAN 50% LIKELY TO BE REALIZED OR PAID BASED UPON TECHNICAL MERITS OF THE POSITION. THE CANCER CENTER CURRENTLY HAS NO TAX BENEFITS OR LIABILITIES RELATED TO UNCERTAIN TAX POSITIONS. 1 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 0 1 MAINTAINING OFFICES, EMPLOYEES OR AGENTS ADMINISTRATIVE SUPPORT 343876 SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 0 1 PROGRAM SERVICES TRAINING & RESEARCH 5036 SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 0 1 GRANTMAKING 57329 CENTRAL AMERICA AND THE CARIBBEAN - ANTIGUA & BARBUDA, ARUBA, BAHAMAS, 0 1 PROGRAM SERVICES RESEARCH 2762 EUROPE (INCLUDING ICELAND & GREENLAND) 0 2 PROGRAM SERVICES RESEARCH 4348 CENTRAL AMERICA AND THE CARIBBEAN - ANTIGUA & BARBUDA, ARUBA, BAHAMAS, 0 0 INVESTMENT 2157084 NORTH AMERICA 0 0 INVESTMENT 778198 0 6 0 0 0 6 3348633 0 3348633 SUB-SAHARAN AFRICA TRAINING & RESEARCH COLLABORATION WITH UNIVERSITY OF GHANA 57329 CASH PAYMENT 0 1 0 1 0 0 1 1 0 PART I, LINE 2: MOFFITT'S PRINCIPAL INVESTIGATOR WORKS IN CONJUNCTION WITH THE RESEARCH FINANCE DEPARTMENT TO MONITOR THE ACTIVITIES OF FOREIGN SUBRECIPIENTS AS NECESSARY TO ENSURE THAT SUBAWARDS ARE USED FOR AUTHORIZED PURPOSES, IN COMPLIANCE WITH FEDERAL STATUTES, REGULATIONS, AND THE TERMS AND CONDITIONS OF THE SUBAWARD; AND THAT SUBAWARD PERFORMANCE GOALS ARE ACHIEVED. MONITORING PROCEDURES INCLUDE REVIEWING FINANCIAL AND PERFORMANCE REPORTS, ENSURING THAT THE FOREIGN SUBRECIPIENT TAKES TIMELY AND APPROPRIATE ACTION ON ANY DEFICIENCIES, AND ISSUING A MANAGEMENT DECISION LETTER FOR GRANT AUDIT FINDINGS TO THE SUBRECIPIENT. DEPENDING ON THE RESULTS OF THE RISK ANALYSIS OF THE SUBRECIPIENT, ADDITIONAL MONITORING TOOLS MAY INCLUDE PROVIDING TRAINING AND TECHNICAL ASSISTANCE ON PROGRAM-RELATED MATTERS, PERFORMING ON-SITE REVIEWS OF THE PROGRAM'S OPERATIONS, ARRANGING FOR AGREED-UPON PROCEDURES ENGAGEMENTS AND AUDITS WHEN FUNDS EXPENDED EQUAL OR EXCEED CERTAIN THRESHOLDS, AND TAKING CORRECTIVE ACTION AGAINST NONCOMPLIANT SUBRECIPIENTS. PART I, LINE 3: ACCRUAL METHOD OF ACCOUNTING WAS USED TO ACCOUNT FOR EXPENDITURES ON SCHEDULE F CONSISTENT WITH THE AUDITED FINANCIAL STATEMENTS. 1 MOFFITT LIFESCIENCES CAMPUS MANAGEMENT CORPORATION 12902 MAGNOLIA DRIVE TAMPA FL 33612 923388291 501C3 4224805 0 INTERCOMPANY SUPPORT H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE HOSPITAL INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238634 501C3 469625 0 INTERCOMPANY SUPPORT AMERICAN CANCER SOCIETY CANCER ACTION NETWORK 250 WILLIAMS ST ATLANTA GA 30303 522340031 501C4 35000 0 SPONSORSHIP CRISTO REY TAMPA HIGH SCHOOL 6400 E CHELSEA ST TAMPA FL 33610 474402991 501C3 32000 0 WORK STUDY PROGRAM BIOFLORIDA INC 6742 FOREST HILL BLVD STE 256 WEST PALM BEACH FL 33413 593436638 501C6 20450 0 SPONSORSHIP NATIONAL PEDIATRIC CANCER 5550 W EXECUTIVE DR SUITE 200 TAMPA FL 33609 593097333 501C3 20000 0 SPONSORSHIP KAY YOW CANCER FUND 4804 PAGE CREEK LN SUITE 118 DURHAM NC 27703 261789695 501C3 15000 0 SPONSORSHIP BEST ACADEMY 10006 CROSS CREEK BLVD TAMPA FL 33647 202834380 501C3 15000 0 SPONSORSHIP GREATER TAMPA CHAMBER OF 201 N FRANKLIN ST STE 201 TAMPA FL 33602 590474960 501C6 10500 0 SPONSORSHIP CONGRESSIONAL WOMEN'S PO BOX 65593 WASHINGTON DC 20035 464755699 501C3 10000 0 SPONSORSHIP AMERICAN LEGISLATIVE EXCHANGE 2900 CRYSTAL DR SUITE 600 ARLINGTON VA 22202 520140979 501C3 10000 0 SPONSORSHIP NATIONAL FOUNDATION FOR WOMEN 5434 CHIEFTAIN CIR STE B ALEXANDRIA VA 22312 521480785 501C3 10000 0 SPONSORSHIP THE POYNTER INSTITUTE 801 THIRD STREET SOUTH ST PETERSBURG FL 33701 591630423 501C3 10000 0 SPONSORSHIP USF ALUMNI ASSOCIATION 4202 E FOWLER AVE ALC 100 TAMPA FL 33620 237357236 501C3 10000 0 SPONSORSHIP CURE ON WHEELS INC 200 2ND AVE SOUTH 475 ST PETERSBURG FL 33701 450568409 501C3 8000 0 SPONSORSHIP TAMPA ORG OF BLACK AFFAIRS 11266 W HILLSBOROUGH AVE STE 328 TAMPA FL 33635 592468415 501C4 7500 0 SPONSORSHIP SOCIETY FOR IMMUNOTHERAPY OF CANCER 555 E WELLS ST SUITE 1100 MILWAUKEE WI 53202 391554806 501C3 6000 0 SPONSORSHIP TAMPA HILLSBOROUGH EDC 101 E KENNEDY BLVD TAMPA FL 33602 271010441 501C6 6000 0 SPONSORSHIP YMCA OF THE SUNCOAST 2469 ENTERPRISE RD CLEARWATER FL 33763 590810731 501C3 50000 0 SPONSORSHIP 14 5 PART I, LINE 2: THE SCHEDULE I, PART II, GRANTS LISTED AS SPONSORSHIPS ARE APPROVED THROUGH THE CHECK REQUEST PROCESS. BECAUSE OF THE NATURE OF THE GRANTS, THE GRANT USE IS NOT MONITORED SINCE THEY ARE GIVEN TO THE ORGANIZATION FOR A SPECIFIC PURPOSE OR EVENT. THE GRANTS LISTED AS INTERCOMPANY SUPPORT ARE ONLY MADE TO RELATED ORGANIZATIONS TO SUPPORT THEIR OPERATIONS. X 0 1 X X X X 1 1 0 0 0 1 1 0 0 PATRICK HWU PRES/CEO 1187819 0 377486 0 9457 0 152929 0 4313 0 1732004 0 0 0 YVETTE M LYONS TREMONTI EVP-CFAO & ASST TREASURER TO 5/2024 772296 0 212568 0 57818 0 362337 0 38529 0 1443548 0 0 0 G DOUGLAS LETSON EVP-PIC TO 6/2024 0 789810 0 219602 0 64208 0 281091 0 27218 0 1381929 0 0 L DAVID DE LA PARTE EVP GEN COUNS & ASST SEC TO 6/2024 643431 0 178715 0 43128 0 365841 0 29834 0 1260949 0 0 0 JOHN CLEVELAND EVP-CENTER DIRECTOR 669390 0 186712 0 45107 0 203472 0 43123 0 1147804 0 0 0 JONATHAN ZAGER CHIEF ACADEMIC OFFICER 0 644450 0 151082 0 4372 0 284682 0 37798 0 1122384 0 0 SARABDEEP SINGH EVP COO 682357 0 185203 0 4902 0 87740 0 38053 0 998255 0 0 0 EDMONDO ROBINSON SVP CHIEF DIGITAL INNOV TO 1/2024 602066 0 139223 0 1710 0 98943 0 36479 0 878421 0 0 0 ANNA GIULIANO DIRECTOR CENTER OF EXCELLENCE 427556 0 68872 0 9269 0 265717 0 37803 0 809217 0 0 0 WJ WILSON VP GOVT RELATIONS 326826 0 76804 0 40284 0 307821 0 16744 0 768479 0 0 0 BRIAN SPRINGER VP RESEARCH ADMINISTRATION 392153 0 74744 0 129047 0 128567 0 34930 0 759441 0 119784 0 JAMES J MULAY ACD TRANSLATIONAL RSCH 492354 0 105130 0 40635 0 81725 0 29439 0 749283 0 0 0 LYNN MOSCINSKI FRM CHIEF ACADEM OFFICER TO 6/2019 0 436709 0 44216 0 18823 0 202207 0 30011 0 731966 0 0 DANA E ROLLISON VP CHIEF DATA OFFICER 376508 0 80416 0 30062 0 219976 0 23550 0 730512 0 0 0 JOANNA WEISS EVP-CFAO & ASST TREAS AS OF 5/2024 407594 0 94914 0 25806 0 158381 0 36877 0 723572 0 0 0 DIANE HAMMON VP CHIEF STRATEGY OFFICER TO 4/2024 431725 0 100409 0 34855 0 53256 0 37424 0 657669 0 0 0 B LEE GREEN FRM VP DIV, PR & STRAT AS OF 8/2022 288120 0 53548 0 4363 0 235441 0 38578 0 620050 0 0 0 RANDA M PERKINS CHIEF MEDICAL INFO OFFICER 317485 0 68942 0 89315 0 66519 0 34588 0 576849 0 0 0 ELSA FLORES ACD BASIC SCIENCE 350852 0 81955 0 1833 0 112150 0 29499 0 576289 0 0 0 CHARLES FLETCHER VP DEPUTY GENERAL COUNSEL 320442 0 75336 0 24686 0 98389 0 36519 0 555372 0 0 0 JARETT RIEGER VP CHIEF INNOVATION OFFICER 267547 0 53627 0 11805 0 181280 0 37557 0 551816 0 0 0 SHELLEY TWOROGER ACD POPULATION SCIENCE 356485 0 66955 0 1195 0 103852 0 16911 0 545398 0 0 0 JOYCE OH VP INFO TECH & CIO 394272 0 70115 0 1368 0 3584 0 37760 0 507099 0 0 0 AMY DURHAM VP-HUMAN RECOURCES OPS 326565 0 68807 0 19162 0 61921 0 26772 0 503227 0 0 0 XAVIER AVAT EVP-CHIEF BUS OFFICER AS OF 7/2023 275098 0 100000 0 102451 0 2205 0 20667 0 500421 0 0 0 HENRY REYES VP-PARTNERSHIP DEVELOP TO 4/2024 197280 125848 0 75464 2983 1864 12214 38733 17176 10756 229653 252665 0 0 DONALD FUTRELL VP PLAN, DESIGN & CONS TO 5/2024 316281 0 75289 0 21306 0 35770 0 30290 0 478936 0 0 0 JASON LEBSACK VP-CLINICAL TRIALS/OPS 296997 0 61682 0 979 0 81367 0 25683 0 466708 0 0 0 EVAN ZASLOW VP PAYER STRATEGIES 0 314903 0 74264 0 722 0 29422 0 37940 0 457251 0 0 CATHY GRANT VP CHIEF DIV, EQTY & INCLUS OFFICER 232975 0 54572 0 15438 0 109235 0 36113 0 448333 0 0 0 LYNN ANSLEY VP-REVENUE CYCLE 257484 0 60461 0 12431 0 70121 0 34497 0 434994 0 0 0 TERRENCE WRIGHT VP-FAC & SUP SVCS 277274 0 65291 0 4142 0 41284 0 35157 0 423148 0 0 0 MERRITT MARTIN VP-PUB AFF, STRAT COMM, COS, EXT AFF 210416 0 24653 0 25711 0 110945 0 34458 0 406183 0 0 0 KENNETH KOMORNY FRM VP CHIEF PHARM OFF AS OF 6/2023 0 252481 0 54985 0 1322 0 56395 0 35874 0 401057 0 0 JOHN JACK MCKENNA SR VP-CHIEF HR OFFICER AS OF 7/2023 325247 0 0 0 54341 0 3371 0 15062 0 398021 0 0 0 SANTOSH MOHAN FRM VP-DIGITAL AS OF 6/2023 157842 0 0 0 189835 0 31624 0 15530 0 394831 0 0 0 PART I, LINE 1A INSTITUTE PAYS MEMBERSHIP DUES TO A SOCIAL CLUB FOR PATRICK HWU, DAVID DE LA PARTE AND W.J. WILSON. THE AMOUNT PAID IS SUBSEQUENTLY ADDED TO TAXABLE WAGES FOR THE RESPECTIVE INDIVIDUAL. PART I, LINE 1B: PAYMENTS MADE FOR SOCIAL CLUB DUES ARE INITIALLY APPROVED BY EXECUTIVE LEADERSHIP AND HUMAN RESOURCES AND REVIEWED/APPROVED BY THE JOINT EXECUTIVE COMPENSATION AND BENEFITS COMMITTEE (JE&BC), APPOINTED BY THE BOARD TO APPROVE SUCH PAYMENTS AND ASSOCIATED AMOUNTS. PART I, LINES 4A-B FOR TAX YEAR 2023, SANTOSH MOHAN RECEIVED SEVERANCE PAYMENTS FROM THE ORGANIZATION IN THE AMOUNT OF $189,507. TO BE ELIGIBLE TO PARTICIPATE IN THE 457(F) NON-QUALIFIED SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN (SERP), PARTICIPANTS MUST ELECT TO CONTRIBUTE AT LEAST 10% ACROSS THE 403(B) AND 457(B) PLANS, AND ARE VESTED AFTER 10 YEARS OF SERVICE. LUMP SUM DISTRIBUTIONS FROM THE ACCOUNT ARE MADE UPON NORMAL RETIREMENT OR TERMINATION. BELOW ARE INDIVIDUALS LISTED ON MOFFITT'S 2023 FORM 990 PART VII, SECTION A, THAT PARTICIPATED IN THE 457(F) SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN AND THEIR RESPECTIVE AMOUNTS OF COMPENSATION CONSTRUCTIVELY RECEIVED IN TAX YEAR 2023 FROM THE PLAN: AMY DURHAM - $15,664 ANNA R. GIULIANO - $1,750 BERNARD L. GREEN - $0 BRIAN C. SPRINGER - $125,187 CATHY GRANT - $3,754 CHARLES R. FLETCHER - $0 DANA E. ROLLISON - $20,968 DIANE K. HAMMON - $27,806 DONALD E. FUTRELL - $11,912 EDMONDO J. ROBINSON - $0 ELSA FLORES - $0 EVAN ZASLOW - $0 G D. LETSON - $46,459 HENRY REYES - $0 JAMES J. MULAY - $30,787 JARETT RIEGER - $10,900 JASON LEBSACK - $0 JOANNA WEISS - $24,396 JOHN L. CLEVELAND - $35,963 JONATHAN S. ZAGER - $1,750 JOYCE OH - $0 KEN KOMORNY - $0 LOUIS D. DE LA PARTE - $32,791 LYNN ANSLEY - $11,912 LYNN C. MOSCINSKI - $1,750 PATRICK HWU - $0 RANDA M. PERKINS - $3,375 SARABDEEP SINGH - $0 SANTOSH MOHAN - $0 SHELLEY S. TWOROGER - $0 TERRENCE WRIGHT - $0 W. J. WILSON - $12,676 YVETTE M. LYONS TREMONTI - $45,116 PART I, LINE 6 IN GENERAL, INCENTIVE COMPENSATION IS BASED ON A PERCENTAGE OF MOFFITT'S NET OPERATING INCOME AND ACHIEVEMENT AGAINST SPECIFIC ORGANIZATIONAL GOALS, DIVISIONAL AND/OR INDIVIDUAL GOALS, PROVIDED A CERTAIN NET OPERATING INCOME THRESHOLD IS MET. A CITY OF TAMPA 591101138 875146AQ5 2016-11-16 58742390 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 B CITY OF TAMPA 591101138 875161CE9 2016-11-03 93832926 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 C CITY OF TAMPA 591101138 875146BD3 2020-06-25 119978935 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 D CITY OF TAMPA 591101138 875161DD0 2020-06-25 302148464 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 A 18010000 61098463 594871 59377759 18519 1107314 2019 0 0 1 1 B 12270000 93846036 92784747 1061289 2010 1 0 1 1 C 120348461 1084744 119247704 16013 2023 0 0 1 1 D 4710000 304612386 2148464 295272152 7191770 2023 0 0 1 1 A 0 0 0 0 0 0 1 B 0 0 0 0 0 0 1 C 0 0 0 0 0 0 1 D 0 0 0 0 0 0 1 A 0 0 0 1 0 0 0 0 1 B 0 0 0 1 0 0 0 0 1 C 0 1 0 1 0 0 1 THE TORONTO DOMINION BANK 1.750000000000 1 0 1 D 0 1 0 1 0 0 1 THE TORONTO DOMINION BANK 1.750000000000 1 0 1 A 1 B 1 C 1 D 1 DATE REBATE COMPUTATION PERFORMED ISSUER NAME: CITY OF TAMPA DATE THE REBATE COMPUTATION WAS PERFORMED: 06/30/2024 ISSUER NAME: CITY OF TAMPA DATE THE REBATE COMPUTATION WAS PERFORMED: 07/01/2023 ISSUER NAME: CITY OF TAMPA DATE THE REBATE COMPUTATION WAS PERFORMED: 06/30/2024 ISSUER NAME: CITY OF TAMPA DATE THE REBATE COMPUTATION WAS PERFORMED: 06/30/2024 ISSUER NAME: PASCO COUNTY FLORIDA DATE THE REBATE COMPUTATION WAS PERFORMED: 06/30/2024 ISSUER NAME: PASCO COUNTY FLORIDA DATE THE REBATE COMPUTATION WAS PERFORMED: 06/30/2024 FORM 990, SCHEDULE K, PART IA COLUMN (F) PROCEEDS OF THE 2016A BOND ISSUANCE WERE USED TO PURCHASE LAND AND BUILDING ON USF CAMPUS AND AN ADDITIONAL MCKINLEY CAMPUS SITE FOR CONSTRUCTION OF RESEARCH AND RESEARCH SUPPORT FACILITIES, CLINICAL AND RESEARCH SUPPORT OFFICES, THE RELOCATION OF CHILD DEVELOPMENT CENTER, AND THE CONSTRUCTION OF RESEARCH LABS. FORM 990, SCHEDULE K, PART IB COLUMN (F) SERIES 2016B IS AN ADVANCE REFUNDING ON SERIES 2007A WHICH WAS USED TO: 1) FINANCE THE COST OF CONSTRUCTION AND EQUIPPING A FOUR STORY ADDITION TO THE MAIN CAMPUS OF THE HOSPITAL, TO INCLUDE 36 ADDITIONAL INPATIENT BEDS, RADIATION ONCOLOGY CLINIC PROGRAM EXPANSION WITH THE ADDITION OF TWO NEW VAULTS USED FOR STATE OF THE ART LINEAR ACCELERATORS, CLINICAL LAB AND PATHOLGY PROGRAM EXPANSION, APPROXIMATELY 40,000 GROSS SQUARE FEET OF FACULTY OFFICE SPACE, AND 1,000 SPACE PARKING GARAGE. 2) FINANCE THE COST OF VARIOUS BACKFILL AND REFURBISHMENT PROJECTS, INCLUDING THE ADDITION OF EIGHT INPATIENT BEDS IN EXISTING SPACE LOCATED AT THE INSTITUTE AND HOSPITAL. FORM 990, SCHEDULE K, PART IC COLUMN (F) PROCEEDS FROM THE 2020A (IN ADDITION TO THE 2020B) BONDS WERE USED FOR: 1) ACQUISITION, CONSTRUCTION, FURNISHING AND EQUIPPING OF VARIOUS MEDICAL AND RESEARCH FACILITIES CAPITAL PROJECTS INCLUDING HOSPITAL EXPANSION PROJECT. 2)VARIOUS FACILITIES, INFRASTRUCTURE SUPPORT, EQUIPMENT, FURNISHINGS, BACKFILL AND REFURBISHMENT PROJECTS. FORM 990, SCHEDULE K, PART ID COLUMN (F) PROCEEDS FROM THE 2020B (IN ADDITION TO 2020A) BONDS WERE USED FOR: 1) ACQUISITION, CONSTRUCTION, FURNISHING AND EQUIPPING OF VARIOUS MEDICAL AND RESEARCH FACILITIES CAPITAL PROJECTS INCLUDING HOSPITAL EXPANSION PROJECT. 2)VARIOUS FACILITIES, INFRASTRUCTURE SUPPORT, EQUIPMENT, FURNISHINGS, BACKFILL AND REFURBISHMENT PROJECTS. FORM 990, SCHEDULE K, PART IE COLUMN (F) PROCEEDS FROM THE 2022A (IN ADDITION TO 2022B) BONDS WERE: 1) DEPOSITED IN AN ESCROW FUND TO CURRENTLY REFUND AND REDEEM THE 2012A REFUNDED BONDS ON SEPTEMBER 1, 2022. 2) COST OF ISSUANCE OF THE SERIES 2022A BONDS. FORM 990, SCHEDULE K, PART IF COLUMN (F) PROCEEDS FROM THE 2022B (IN ADDITION TO 2022A) BONDS WERE: 1) DEPOSITED IN AN ESCROW FUND TO CURRENTLY REFUND AND REDEEM THE 2012B REFUNDED BONDS ON JULY 1, 2022. 2) COST OF ISSUANCE OF THE SERIES 2022B BONDS. FORM 990, SCHEDULE K, PART IG COLUMN (F) PROCEEDS FROM THE 2023A BONDS WILL BE USED FOR: 1) FINANCING OR REFINANCING, THE ACQUISTION, DEVELOPMENT, CONSTRUCTION, EQUIPPING, FURNISHING AND IMPROVEMENT OF VARIOUS MEDICAL AND RESEARCH FACILITIES, INCLUDING ONE OR MORE RESEARCH BUILDINGS, PROTON THERAPY CENTERS, AND MOFFITT AMBULATORY CLINIC. 2)OTHER CAPITAL EXPENSES ASSOCIATED WITH THE SPEROS FL PROJECT IN PASCO COUNTY, FLORIDA. 3) COST OF ISSUANCE OF THE SERIES 2023A BONDS. FORM 990, SCHEDULE K, PART IH COLUMN (F) PROCEEDS FROM THE 2023B BONDS WILL BE USED FOR: 1) FINANCING ADDITIONAL COSTS OF CONSTRUCTION AND EQUIPMENT OF PASCO HOSPITAL AMBULATORY FACILITY. 2) HOSPITAL AND REASEARCH FACILITY AND RELATED EQUIPMENT FOR SOUTHSHORE (HILLSBOROUGH). 3) ADDITIONAL HEALTHCARE INFRASTRUCTURE ON MAGNOLIA AND MCKINLEY CAMPUSES. 4) COST OF ISSUANCE OF THE SERIES 2023B BONDS. FORM 990, SCHEDULE K, PART II THE DIFFERENCE BETWEEN THE ISSUE PRICE IN SCHEDULE K, PART I AND TOTAL PROCEEDS OF THE ISSUE IN PART II, LINE 3 FOR EACH ISSUE IS INVESTMENT EARNINGS. A HILLSBOROUGH CTY INDUSTRIAL DEV AUTHORITY 591293512 43232YBJ3 2022-06-06 88408325 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 B HILLSBOROUGH CTY INDUSTRIAL DEV AUTHORITY 591293512 43233AFU5 2022-04-04 19500545 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 C PASCO COUNTY FLORIDA 596000793 70252AAX3 2023-03-15 352942534 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 D PASCO COUNTY FLORIDA 596000793 70252CAA9 2023-09-21 210786000 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 A 11230000 88902898 88464766 438132 2016 1 0 1 1 B 4365000 19523997 19406494 117503 2022 1 0 1 1 C 374958805 1997958 4375100 18722422 349863325 2026 0 0 0 1 D 218148175 1540561 48586606 168021008 2026 0 0 0 1 A 0 0 0 1 1 0.00500 0.00500 0 0 1 B 0 0 0 0 0 0 1 C 0 0 0 0 0 0 1 D 0 0 0 0 0 0 1 A 0 1 0 0 0 0 0 0 1 B 0 1 0 0 0 0 0 0 1 C 0 1 0 1 0 0 0 0 1 D 0 1 0 1 0 0 0 0 1 A 1 B 1 C 1 D 1 AVEMARIE BOBB-MORGAN FAMILY OF OFFICER, CATHY GRANT 81751 EMPLOYEE COMPENSATION 0 X EQUIPMENT 43 19773519 PURCHASE PRICE 0 0 0 0 PART I, COLUMN (B): THE NUMBER ON LINE 25(B) REPRESENTS THE NUMBER OF CONTRIBUTIONS, NOT THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS AND OFFICERS, THAT JOINTLY SERVE ON THE INSTITUTE AND A FOR-PROFIT RELATED ENTITY, QUALIFY AS HAVING A BUSINESS RELATIONSHIP. INSTITUTE & MOFFITT TECHNOLOGIES CORPORATION (MTC): LOUIS D. DE LA PARTE, OFFICER INSTITUTE & MTC OFFICER YVETTE M. LYONS TREMONTI, OFFICER INSTITUTE & MTC OFFICER PATRICK HWU, OFFICER INSTITUTE & MTC OFFICER JOHN CLEVELAND, OFFICER INSTITUTE & MTC OFFICER CHARLES FLETCHER, OFFICER INSTITUTE & MTC OFFICER IN ADDITION, THE FOLLOWING INDIVIDUALS HAVE INVESTED IN THE SAME COMPANIES IN WHICH MOFFITT DOES BUSINESS: 1) EDWARD DROSTE AND GEOFFREY DUYK - BUSINESS RELATIONSHIP 2) TIM ADAMS AND JOSEPH CABALLERO- BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B PRIOR TO ELECTRONICALLY FILING FORM 990 (RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX), A COPY OF THE RETURN IS PROVIDED TO THE JOINT FINANCE COMMITTEE, CONSISTING OF BOARD MEMBERS ACROSS THE CANCER CENTER, GIVING EACH MEMBER TIME TO REVIEW THE RETURN. BOARD MEMBERS HAVE THE OPPORTUNITY TO ASK QUESTIONS RELATED TO THE INFORMATION PROVIDED ON THE RETURN. THE FORM 990 IS ALSO PROVIDED TO THE CHIEF FINANCIAL OFFICER FOR REVIEW. BASED ON THE REVIEW ANY SUGGESTED COMMENTS OR CHANGES ARE DISCUSSED, AND IF DEEMED NECESSARY CHANGES ARE MADE PRIOR TO SIGNING. FORM 990, PART VI, SECTION B, LINE 12C ON AN ANNUAL BASIS A PRESENTATION IS MADE TO RESEARCH BOARD MEMBERS TO REVIEW THE CONFLICT OF INTEREST POLICY AND PROCEDURES FOR DISCLOSING ANY POTENTIAL CONFLICTS. EACH DIRECTOR, OFFICER, COMMITTEE MEMBER, AND KEY EMPLOYEE SHALL COMPLETE A CONFLICT OF INTEREST DISCLOSURE CERTIFICATION VIA THE ELECTRONIC DISCLOSURE SYSTEM. ANY DIRECTOR, OFFICER, COMMITTEE MEMBER, OR KEY EMPLOYEE WHO REASONABLY BELIEVES THAT HE OR SHE MAY HAVE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST MUST DISCLOSE THE EXISTENCE OF AND THE MATERIAL FACTS OF THE NATURE OF HIS/HER INTEREST ON THE FORM. THE ELECTRONIC FORM IS SUBMITTED TO THE CORPORATE COMPLIANCE OFFICE, WHICH REVIEWS THE FORMS, GATHERS ADDITIONAL RELEVANT INFORMATION WHERE NECESSARY, AND PREPARES A SUMMARY OF THE DISCLOSURES TO BE REVIEWED BY THE CONFLICT OF INTEREST WORK GROUP. IF A DIRECTOR OR COMMITTEE MEMBER DISCLOSES THAT HE/SHE HAS A POTENTIAL CONFLICT OF INTEREST AT A BOARD OR COMMITTEE MEETING, SUCH DIRECTOR OR COMMITTEE MEMBER MUST DISCLOSE THE NATURE OF THE INTEREST AND ANY RELATED INFORMATION AND RESPOND TO QUESTIONS AS MAY BE REQUIRED BY THE REMAINING MEMBERS. BASED ON THE INFORMATION DISCLOSED, THE REMAINING BOARD MEMBERS WILL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF A CONFLICT EXISTS THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER AN ALTERNATIVE TRANSACTION OR ARRANGEMENT THAT WOULD NOT GIVE RISE TO A CONFLICT IS EQUALLY ADVANTAGEOUS. IF AN ALTERNATIVE TRANSACTION IS NOT EQUALLY ADVANTAGEOUS THE DIRECTOR OR COMMITTEE MEMBER WHO IS THE SUBJECT OF THE CONFLICT SHALL NOT VOTE ON, NOR USE HIS/HER PERSONAL INFLUENCE ON, NOR PARTICIPATE IN DISCUSSIONS OR DELIBERATIONS WITH RESPECT TO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 THE INSTITUTE HAS AN ESTABLISHED SUB-COMMITTEE, THE JOINT EXECUTIVE COMPENSATION & BENEFITS COMMITTEE (JEC&BC) THAT IS MADE UP ENTIRELY OF INDEPENDENT, OUTSIDE COMMITTEE MEMBERS. THIS COMMITTEE IS CHARGED WITH THE OVERSIGHT OF THE COMPENSATION OF MOFFITT DISQUALIFIED PERSONS. THESE POSITIONS INCLUDE THE CEO, EXECUTIVE VICE PRESIDENTS, CHIEF HUMAN RESOURCES OFFICER, CHIEF ENTERPRISE RISK OFFICER, VP FINANCE, VP MOFFITT MEDICAL GROUP, VP PATIENT CARE SERVICES/CHIEF NURSING OFFICER AND VP CHIEF PHARMACY OFFICER. TO ACCOMPLISH ITS MISSION, THE COMMITTEE CAN, AS NEEDED, AND DOES AT ITS DISCRETION, ENGAGE INDEPENDENT OUTSIDE ADVISORS, INCLUDING, BUT NOT LIMITED TO ATTORNEYS AND THIRD-PARTY COMPENSATION CONSULTANTS. ON AN ANNUAL BASIS THE JEC&BC ENGAGES A NATIONALLY KNOWN, THIRD-PARTY CONSULTING FIRM TO PROVIDE A DETAILED STUDY OF THE CASH COMPENSATION FOR EACH DISQUALIFIED PERSON. THE CONSULTANT USES A VARIETY OF PUBLISHED SURVEYS COMPILED BY INDEPENDENT FIRMS TO PROVIDE THE INSTITUTE SOURCE DATA FOR THE STUDY. USING FUNCTIONALLY COMPARABLE POSITIONS IN OTHER SIMILARLY SIZED, NOT-FOR-PROFIT AND FOR-PROFIT HEALTHCARE, ACADEMIC AND RESEARCH ORGANIZATIONS, THE CONSULTING FIRM PRODUCES A STUDY THAT COMPARES EACH DESIGNATED MOFFITT POSITION TO ITS APPROPRIATE MARKET EQUIVALENT, INCLUDING THE VALUE OF ALL BENEFITS AND PERQUISITES (CASH AND NON-CASH) PROVIDED AS COMPENSATION TO THE DISQUALIFIED PERSONS. THE RESULTING DATA IS PROVIDED TO THE DIRECTOR OF COMPENSATION, WHO IS NOT INCLUDED IN THE DISQUALIFIED PERSON CATEGORY, FOR USE IN THE FORMULATION OF RECOMMENDATIONS FOR COMPENSATION CHANGES TO MAINTAIN MARKET COMPETITIVENESS OR TO REWARD PERFORMANCE. THESE RECOMMENDATIONS, ALONG WITH THE CONSULTANT'S COMPARABILITY DATA, ARE PRESENTED TO THE JEC&BC FOR THE COMMITTEE MEMBERS TO CONFIRM ITS REASONABLENESS, MAKE MODIFICATIONS AS IT DEEMS NECESSARY AND PROVIDE FINAL APPROVAL. MINUTES ARE KEPT AT EACH OF THESE ANNUAL MEETINGS DETAILING THE RECOMMENDATIONS PRESENTED AND THE DECISIONS MADE BY THE COMMITTEE. THESE MINUTES ARE PUBLISHED TO THE COMMITTEE AT THE NEXT MEETING AND REPORTED BACK TO THE INSTITUTE BOARD. FORM 990, PART VI, SECTION C, LINE 19 MOFFITT RESEARCH MAKES AVAILABLE TO THE PUBLIC THROUGH DAC BOND, THIRD PARTY VENDORS' WEBSITE AND MOFFITT'S WEBSITE THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS. IN ADDITION FORM 990 IS MADE AVAILABLE ON GUIDESTAR AS WELL AS ON MOFFITT'S WEBSITE. ALL ORGANIZING AND GOVERNING DOCUMENTS SUCH AS FORM 1023, CONFLICTS OF INTEREST POLICY, AND BYLAWS AS WELL AS FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION B, LINE 16B: THE ORGANIZATION HAS ADOPTED A WRITTEN JOINT VENTURE PROCEDURE WITH WHICH IT COMPLIES. IN MARCH 2021, MOFFITT ENTERED INTO A LIMITED PARTNERSHIP AGREEMENT WITH CERTAIN INVESTORS TO FORM M2GEN HOLDINGS, L.P. WHERE THE CANCER CENTER'S OUTSTANDING EQUITY INTEREST IN M2GEN, CORP. WAS EXCHANGED FOR A PARTNERSHIP INTEREST IN M2GEN HOLDINGS, L.P. THE CANCER CENTER OWNS APPROXIMATELY 18.6% OF OUTSTANDING PARTNERSHIP UNITS. THE CANCER CENTER DOES NOT HAVE THE ABILITY TO EXERCISE SIGNIFICANT INFLUENCE OVER THE OPERATING AND FINANCIAL DECISIONS OF M2GEN HOLDINGS, L.P. M2GEN OPERATIONS INVOLVE ONCOLOGY FOCUSED HEALTH INFORMATICS SOLUTIONS WITH THE MISSION TO HELP PATIENTS GET ACCESS TO THE BEST TREATMENTS BY LEVERAGING CLINICAL AND MOLECULAR DATA TO TAILOR PERSONALIZED THERAPIES. DUE TO CONTINUED LOSSES, THE VALUE OF THE INVESTMENT IN M2GEN HOLDINGS, L.P. WAS ESTIMATED TO BE -0- AT JUNE 30, 2024. IN ADDITION, THE CANCER CENTER WAS THE CONTROLLING SHAREHOLDER OF A FOR-PROFIT SUBSIDIARY CORPORATION, KAPADI, INC. (FORMERLY ONCOBAY CLINICAL, INC.) THROUGH JANUARY 2, 2023. ON JANUARY 3, 2023, THE CANCER CENTER ENTERED INTO A STOCK PURCHASE AGREEMENT WITH CERTAIN INVESTORS FOR A CONTROLLING INTEREST IN THE CANCER CENTER'S EQUITY INTEREST IN KAPADI, INC. AS A RESULT OF THE TRANSACTION, THE CANCER CENTER RETAINED COMMON SHARES OF APPROXIMATELY 20% RECORDED AS AN INVESTMENT USING THE COST METHOD. KAPADI, INC.'S OPERATIONS INVOLVE PARTNERING WITH BIOPHARMACEUTICAL COMPANIES, PHYSICIANS, AND INSTITUTIONS TO ACCELERATE INNOVATIVE CLINICAL RESEARCH. ON AN ONGOING BASIS, FOR NEW AND EXISTING ARRANGEMENTS SUCH AS THESE, MOFFITT FOLLOWS PROCEDURES THAT REQUIRE THE EVALUATION OF ITS PARTICIPATION IN THESE ARRANGMENTS AND TAKES ANY NECESSARY STEPS TO SAFEGUARD ITS EXEMPT STATUS. FORM 990, PART VIII, LINE 7 DURING THE YEAR, THE CANCER CENTER RECEIVED CERTAIN "EARN-OUT" PAYMENTS TOTALING $16,417,016 WHICH RELATED TO THE SALE OF AN INVESTMENT THAT OCCURRED IN THE PREVIOUS TAX YEAR. PURSUANT TO THE SALE AGREEMENT, THESE PROCEEDS HAVE BE TREATED AS AN ADJUSTMENT TO THE SALE PRICE AND HAVE BEEN INCLUDED ON LINE 7A WITH NO ASSOCIATED COST REPORTED ON LINE 7B. FORM 990, PART IX, COLUMN (D): THERE ARE NO FUNDRAISING EXPENSES BECAUSE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION, INC. HANDLES ALL FUNDRAISING ACTIVITIES FOR H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. AND ITS SUBSIDIARIES. FORM 990, PART IX, LINE 24B CERTAIN MOFFITT CANCER CENTER INTERCOMPANY OVERHEAD HAS BEEN ALLOCATED FROM THE PARENT ENTITY TO THE SUBSIDARY ENTITIES AND THOSE AMOUNTS ARE INCLUDED IN COLUMN (C) AND THEN REALLOCATED ON LINE 24B TO THE PROPER FUNCTIONAL CATEGORIES. FORM 990, PART XI, LINE 9: TRANSFER TO/FROM AFFILIATED ORGS (CASH) 156,470,436. CHANGE IN INTEREST IN NET ASSETS OF FOUNDATION 11,958,796. GRANT REFUNDS & ADJUSTMENTS -945,289. INTEREST FROM THE CIGARETTE TAX TRUST FUND 11,747. H LEE MOFFITT CANCER CTR & RESEARCH INSTITUTE HOSPITAL INC 12902 MAGN0LIA DRIVE TAMPA FL 33612 593238634 PATIENT CARE FL 501(C)(3) LINE 3 H LEE MOFFITT CANCER CTR & RES INST INC 1 H LEE MOFFITT CANCER CTR & RESEARCH INSTITUTE FOUNDATION INC 12902 MAGN0LIA DRIVE TAMPA FL 33612 593238636 FUNDRAISING FL 501(C)(3) LINE 7 H LEE MOFFITT CANCER CTR & RES INST INC 1 H LEE MOFFITT CC&RI LIFETIME CANCER SCREENING CENTER INC 12902 MAGN0LIA DRIVE TAMPA FL 33612 593238640 PRACTICE MANAGEMENT FL 501(C)(3) LINE 10 H LEE MOFFITT CANCER CTR & RES INST INC 1 MOFFITT REAL ESTATE HOLDING CORP 12902 MAGNOLIA DRIVE TAMPA FL 33612 923387708 HOLDING TITLE FL 501(C)(2) H LEE MOFFITT CANCER CTR & RES INST INC 1 MOFFITT LIFESCIENCES CAMPUS MANAGEMENT CORPORATION 12903 MAGNOLIA DRIVE TAMPA FL 33613 923388291 REAL ESTATE PROPERTY MANAGEMENT FL 501(C)(3) LINE 12A, I H LEE MOFFITT CANCER CTR & RES INST INC 1 MOFFITT TECHNOLOGIES CORPORATION 12902 MAGNOLIA DRIVE TAMPA FL 33612 300332914 TECHNOLOGY MANAGEMENT FL H LEE MOFFITT CC&RI INC C 262621 1.00000 1 0 1 1 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0 1 H LEE MOFFITT CC&RI HOSPITAL INC B 469625 FMV H LEE MOFFITT CC&RI HOSPITAL INC C 20596052 FMV H LEE MOFFITT CC&RI FOUNDATION INC C 16744724 FMV H LEE MOFFITT CC&RI FOUNDATION INC Q 6311008 FMV MOFFITT LIFESCIENCES CAMPUS MANAGEMENT CORPORATION B 4224805 FMV